The historic impact of two category 4 hurricanes from the Atlantic in the same year is a hard... Read More
The historic impact of two category 4 hurricanes from the Atlantic in the same year is a hard reminder that weather is playing an increasingly bigger role on our lives. 2016 was the warmest year on... Read More
The market has been intensely concentrated all year on the Federal Reserve’s plan to increase... Read More
The market has been intensely concentrated all year on the Federal Reserve’s plan to increase interest rates. That focus has weighed on rate-sensitive sectors and threatened to drive investors... Read More
Record sales since the recession are starting to weigh on the automotive industry, signaling that... Read More
Record sales since the recession are starting to weigh on the automotive industry, signaling that the group may be entering a deep cyclical crisis. Prices on used cars and new trade-ins are plunging... Read More
Fidelity recently released its annual study of retirement health care costs. The news, as it has... Read More
Fidelity recently released its annual study of retirement health care costs. The news, as it has been for the last decade, is not good. A newly-retired, 65-year old couple will need an... Read More
The opening of gaming resorts in Macau (China) in 2004 was a boon to casino stocks. By the first... Read More
The opening of gaming resorts in Macau (China) in 2004 was a boon to casino stocks. By the first full year of operations, Macau casinos were reporting $6.2 billion in revenue and more than twice the... Read More
The president’s call for a $1 trillion increase in infrastructure spending seems to have been... Read More
The president’s call for a $1 trillion increase in infrastructure spending seems to have been put on hold, depressing investor sentiment for construction and infrastructure stocks this... Read More
After a tough 2016 due to political pressure, drug-makers looked to be having a good year. The SPDR... Read More
After a tough 2016 due to political pressure, drug-makers looked to be having a good year. The SPDR S&P Pharmaceuticals ETF (NYSE: XPH) reached a 2017 high of $44.32 in late July, up nearly 14%... Read More
To say retailers have had a tough time this year is an understatement. The SPDR S&P Retail ETF... Read More
To say retailers have had a tough time this year is an understatement. The SPDR S&P Retail ETF (NYSE: XRT) is down more than 6%, underperforming the S&P 500 by almost 17% to date. The... Read More
I watch insider transactions closely, following the big selling just as much as the buying. The... Read More
I watch insider transactions closely, following the big selling just as much as the buying. The conventional wisdom is that the actions of these investors can tell you when to buy or sell a company.... Read More